New glioblastoma cancer vaccine shows promise in phase 2 trial

June 6 2011

The first results of a multicenter Phase 2 clinical trial on a new brain cancer vaccine tailored to a patient's own tumor will be announced on Monday at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

The trial, conducted at three U.S. medical centers and led by doctors at the University of California, San Francisco Medical Center, found that the vaccine was safe and less toxic than conventional treatments and that it could extend survival for people with recurrent glioblastoma - a deadly type of brain cancer that kills thousands of Americans every year.

The trial involved 33 patients with recurrent glioblastoma treated at UCSF's Helen Diller Family Comprehensive Cancer Center, at the Seidman Cancer Center at University Hospitals Case Medical Center in Cleveland and at NewYork - Presbyterian Hospital/Columbia University Medical Center in New York City.

"The vaccine induces an immune response against multiple tumor-specific targets that allows patients to fight their own disease," said UCSF neurosurgeon Andrew Parsa, MD, PhD, who led the research. "The survival data thus far compare favorably with historical controls and clearly support advancement of this vaccine into later-stage randomized trials to directly compare the vaccine's effectiveness to conventional treatment."

Without treatment, half of the patients in the trial would have
succumbed to the cancer within five to nine months, based on historical
data. After receiving the vaccine, however, the median survival for 30
patients who received at least four vaccinations was 11 months. Several
have survived for more than a year.

"These results are encouraging," said Andrew Sloan, MD, director of the
Brain Tumor and Neuro-Oncology Center at University Hospitals Case
Medical Center and Peter D. Cristal Chair in Neurosurgery at Case
Western Reserve University School of Medicine. The next step, Sloan
agrees, would be a more extensive, randomized clinical trial.

A second objective of the current trial was to see if the vaccine could
produce an immune response in all patients, and the results showed that
it did so in every patient in the trial tested to date. This suggests that
doctors may be able to extend survival even longer by combining the
vaccine with other drugs that enhance this immune response.

"This study confirms our theory that a vaccine is capable of causing a
favorable immune response in patients with brain tumors," said Jeffrey
Bruce, MD, Edgar M. Housepian Professor of Neurological Surgery
Research at New York-Presbyterian Hospital/Columbia University
Medical Center. "Our goal now is to conduct further clinical studies to
demonstrate that this heat shock protein vaccine can clearly help brain
tumor patients live longer."

**A Deadly Form of Brain Cancer**

Some 17,000 Americans are diagnosed with glioblastoma every year,
Parsa said, and only 2 percent of them survive longer than five years -
even with treatment.

Glioblastoma treatment generally begins with a surgical resection, in
which neurosurgeons remove the cancerous tissue from the brain. These
surgeries are fairly common at large medical centers, and neurosurgeons at UCSF Medical Center perform approximately 850 a year.

The surgery usually is followed by radiation therapy and then chemotherapy to kill any remaining cancer cells. Many people undergo treatment only to have the cancer return a few months later, at which point doctors may operate again, followed by more chemotherapy.

Cancer vaccines are a relatively new approach that has appeared in the last decade. Last year, the U.S. Food and Drug Administration approved the first therapeutic cancer vaccine for prostate cancer, and several more cancer vaccines are in clinical trial.

The basic concept is similar to a vaccine for a disease like measles or mumps: an injection in the arm induces an immune response that helps the body fight the particular pathogen - or in this case, the cancer. An effective immune response would then shrink tumors and extend lives.

The problem with glioblastoma patients is that the immune responses induced by vaccines have historically been limited: either they did not kill all of the tumor cells or they worked on some patients but not on others.

**A New Hope**

Hoping to initiate new approaches to fighting recurrent glioblastoma, several brain cancer advocacy groups pooled their resources and approached doctors at leading cancer centers few years ago, requesting research proposals. Parsa and his colleagues proposed a new type of cancer vaccine based on tiny molecular bundles called heat shock proteins.

After completing a Phase 1 safety trial in 2008, Parsa and his colleagues
began enrolling patients in the single-arm Phase 2 trial to test the efficacy of the vaccine by comparing overall survival to historical controls.

The Phase 2 trial also was partially paid for with matching funds provided by the National Institutes of Health, but Parsa credits the American Brain Tumor Association, Accelerate Brain Cancer Cure and the National Brain Tumor Society with spearheading the effort.

"It never would have happened without them," Parsa said. "Patient advocacy groups are an important component of how we inform patients about this disease. These groups are also increasingly critical to funding translational research, which bridges the gap between the laboratory and the clinic."

Once a tumor was surgically removed from a patient in the trial, it was sent to the biotech company Agenus, Inc., which prepared a vaccine specific for that patient. The company shipped the vaccine back to the doctors who would inject it into the patient's arm several times over the course of the year.

In the end, they demonstrated that the new vaccine is a feasible, safe and effective treatment for glioblastoma. Agenus, Inc. is now preparing for a larger, randomized clinical trial.

Parsa has not received any personal financial support or travel expense reimbursement for this work from Agenus or for consulting activities on behalf of Agenus. Neither Parsa nor UCSF has an equity interest in Agenus or other financial relationship with the company.

More information: The poster, "Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a Phase 2 multicenter clinical trial with immunological
assessments," by A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang, J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados, A. E. Sloan, J. N. Bruce will be presented at 8:00 a.m. CT on Monday, June 6th in Hall A of the McCormick Place Convention Center in Chicago, IL. ABSTRACT:
abstract.asco.org/AbstView_102_85010.html

Provided by University of California, San Francisco

Citation: New glioblastoma cancer vaccine shows promise in phase 2 trial (2011, June 6) retrieved 8 October 2023 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.